DNALinux logo

DNALinux is a Live Linux for bioinformatic use. Just boot your computer and have several bioinformatic software. Download and use it free.

Biomarker World Congress 2009 PDF Print E-mail
Written by Administrator   
Thursday, 19 March 2009 17:15
Register by April 10, 2009 and-SAVE
Cambridge Healthtech Institute's Fifth Annual
May 27-29, 2009 | Loews Philadelphia Hotel | Philadelphia, Pennsylvania
Click here to download the final brochure pdf. (no forms)

Comprehensive Coverage of Biomarkers In:
  • Assay Development
  • Molecular Diagnostics
  • Clinical Pharmacology
  • Translational Medicine
  • Clinical Trials
  • Safety Assessment
  • Personalized Medicine
  • Go/No-Go Decision Making
  • Oncology Drugs & Diagnostics

Distinguished Faculty

Pre-Conference Events:
Wednesday, May 27

  • Executive ThinkTank: Collaborations, Consortia, and Funding Opportunities in Biomarker Development
  • Short Course: Fit-for-Purpose Biomarker Assay Development & Validation
  • Workshop: Biomarkers for Cancer Drug Development

Click here for full pre-conference event details.

Conference at a Glance

Main Conference
Wednesday, May 27

Plenary Keynotes

  • Predictive Biomarkers: Using What's Been Learned from Past Regulatory Decisions to Inform Future Development Plans
    Lawrence J. Lesko, Ph.D., F.C.P., Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

  • Genetic and Metabolomic Markers of Disease Risk
    C. Thomas Caskey, M.D., F.A.C.P., Director & Chief Executive Officer, The Brown Foundation Institute of Molecular Medicine and Genetics, The University of Texas, Health Science Center at Houston
Thursday, May 28

Delivering on the Promise of Personalized Medicine

  • Biomarkers in Personalized Health Care: Opportunities, Challenges, Approaches
    Klaus Lindpaintner, M.D., M.P.H., Head, Medical Genomics & Vice President, Research, F. Hoffmann-La Roche AG

  • Personalized Medicine: Turning Promise into Reality
    Geert Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.

  • Promulgating use of Pharmacogenomics Tests on a National Level: The Medco Experience
    Robert E. Epstein, M.D., M.S., Senior Vice President, Medical & Analytical Affairs; Chief Medical Officer, Medco Health Solutions, Inc.
  • A Business Context for Personalized Medicine Research & Development
    Brian B. Spear, Ph.D., Director, Scientific Affairs, Global Pharmaceutical Research and Development, Abbott Labs
  • Biostatistics Challenges in Personalized Medicine
    Kwan Lee, Ph.D., Senior Director, Department of Biostatistics and Data Management, GlaxoSmithKline

Biomarker Adoption in Clinical Trials

  • Considerations on the Level of Evidence for Biomarker Adoption
    Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
  • Biomarkers in Drug Development Compared to Medical Practice: Overlaps, Gaps, and Flaps
    Linda C. Surh, M.D., Ph.D., FRCPC, Director, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline, UK
  • Use of a Surrogate Biomarker as an Efficacy Endpoint in Clinical Trials and a Monitoring Tool in Routine Patient Management
    Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals

Molecular Diagnostics for Personalized Medicine

  • Predictive Biomarkers in Clinical Development
    Darren Hodgson, Ph.D., Biomics Advisor,Oncology Therapy Area, AstraZeneca
  • Strategies for Companion Diagnostic Development in a Pharmaceutical Research & Development Setting
    John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.
  • Regulatory Perspective of the Role of In Vitro Diagnostics in Personalized Medicine
    Alberto Gutierrez, Ph.D., Deputy Director, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), U.S. Food and Drug Administration
  • Therapy Decisions in Breast Cancer Based on Molecular Diagnostics
    Christoph Petry, Ph.D., Head, Molecular Research Germany, Siemens Healthcare Diagnostics Products GmbH

Clinical Pharmacology

  • Application of Pharmacodynamic Markers for Proof of Principle
    Hans Winkler, Ph.D., Senior Director & Global Head, Oncology Biomarkers, Pharmaceutical Research & Development, Johnson & Johnson
  • Translational Pharmacology: Using PD-Biomarkers and PK/PD Modeling to Bridge Preclinical and Clinical Pharmacology
    Paul J. Fielder, Ph.D., Senior Director & Senior Scientist, Early Development Pharmacokinetics, Pharmacodynamic and Bioanalytical Sciences,Genentech, Inc.
  • Developing Biomarkers for Proof-of-Pharmacology
    Mark Fidock, Ph.D., Head, Biochemical and Molecular BioMarkers, Experimental Biological Sciences, Pfizer Limited
  • Value of Biomarkers in the Oncology Therapeutic Area in Proof-of-Concept Clinical Evaluations
    Chetan Lathia, Ph.D., Director, Global Clinical Pharmacology, Bayer Corp.
Friday, May 29

Biomarkers in Translational Medicine

  • Translational Medicine in the Pharmaceutical Industry: Addressing Multiple Challenges in the New Environment
    Giora Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research
  • Biomarkers in Translational Medicine: Importance of Technological and Operational Innovation
    Ole Vesterqvist, Ph.D., Senior Director, Biomarker Lab & Outsourcing, Clinical Translational Medicine, Wyeth Research

Toxicity Biomarkers

  • Predictive Safety Biomarkers in Non-Clinical Development
    Phil Hewitt, Ph.D., Head, Molecular Toxicology, Institute of Toxicology, Merck KGaA
  • Identification of Proteasome Gene Regulation in a Rat Model for Hyperlipidemia using Microarray Analysis
    Jeffrey Waring, Ph.D., Associate Research Fellow & Group Leader, Cellular & Molecular Toxicology, Abbott Labs
  • Tissue-Specific, Non-Invasive Biomarkers for Pre-Clinical Safety Assessment
    Patrick Y. Mueller, Ph.D., Project Leader, Safety Assessment, Novartis Pharma AG
  • Finding Biomarkers that Predict Rare Adverse Events: Assessing the Risk for Acute Idiosyncratic Hepatocellular Injury (AIHI)
    John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.

Biomarker Assay Development

  • The Next Challenge for Biomarker Assay Development to Monitor Drug Effects
    Francois Legay, Ph.D., Global Head, Marker Localization & Assays, Novartis Pharma AG
  • The Critical Role of Characterizing Emerging Technologies Prior to Biomarker Development
    Michael E. Burczynski, Ph.D., Associate Director, Biomarker Lab, Clinical Translational Medicine, Wyeth Pharmaceuticals

Biomarker Qualification: Biological and Analytical Validation

  • Biomarker Development and their Clinical Qualification
    Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. Food and Drug Administration
  • Critical Path Institute: Collaboration Towards Biomarker Qualification
    Maryellen de Mars, Ph.D., Director, Clinical Biomarkers, The Critical Path Institute
  • Biospecimen Research to Enable Molecular Medicine
    Helen M. Moore, Ph.D., Director, Biospecimen Research Network, National Cancer Institute, National Institutes of Health
  • RNA Readouts as Clinical Biomarkers
    Stewart Bates, Ph.D., Director, Stevenage Core Technologies Group, Discovery Technology Group, GlaxoSmithKline

Close of Conference


Sponsorship Opportunities
Brand your company as a thought leader in the global biomarker community by participating as an active Sponsor. Showcasing your technologies, services and solutions to our highly targeted audience can significantly impact their buying decisions and help you achieve your sales and business development objectives.
Corporate Support Sponsor: Covidien

Exhibitor Information | Sponsorship Information | Exhibitor Prospectus | Demographics | Exhibitor Contract